Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial-MedSci.cn

Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial

Breder, I; Wolf, VLW; Soares, AAS; de Carvalho, LSF; Kimura-Medorima, ST; Cintra, RM; Barreto, J; Munhoz, DB; Cunha, JS; Bonilha, I; Coelho, OR; Quinaglia, T; Nadruz, W; Guerra, G; Muscelli, E; Sposito, AC

Sposito, AC (通讯作者)，State Univ Campinas Unicamp, Lab atherosclerosis & Vasc Biol, AteroLab, Dept Cardiol, BR-13084971 Campinas, SP, Brazil.

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial

科室

工具

服务